The Global AcetazolamideMarket, by Formulation (Tablets, Capsules, and Injection), by Application(Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention,Heart Failure, and Seizures), By Distribution Channel (Hospital Pharmacy,Retail Pharmacy, and Online Pharmacy), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 191.8million in 2018, and is projected to exhibit a CAGR of 4.8% during the forecastperiod (2018 - 2026).
Acetazolamide is one of the mostpreferred medication for glaucoma incidences as it helps in relieving symptomsand reduces risk of serious complications among patients of glaucoma.Acetazolamide is sold under different trade names including AZM, Diamox,Acemox, Evamox, and Setacar. The drug is used to treat glaucoma, epilepsy,attitude sickness, and heart failure induced edema.
Browse 23 Market Data Tables and25 Figures spread through 152 Pages and in-depth TOC on "AcetazolamideMarket, by Formulation (Tablets, Capsules and Injection), by Application(Glaucoma, Epilepsy, Drug-induced Edema, Altitude Sickness, Fluid Retention,Heart Failure and Seizures), By Distribution Channel (Hospital Pharmacy, RetailPharmacy, and Online Pharmacy) and by Region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2396
Furthermore, key players areengaged in launching acetazolamide-based products along with gaining regulatoryapproval for the same in the market. For instance, in November 2017, StridesPharma Global Pte. Ltd. — subsidiary of Strides Shasun Limited—receivedapproval from the U.S. Food and Drug Administration (FDA) for acetazolamidetablets, 125 mg and 250 mg, a generic version of Diamox Tablets. Acetazolamidetablet is used to prevent and reduce the symptoms of altitude sickness andtreat a certain type of eye problem (open-angle glaucoma). In the U.S.,company’s acetazolamide tablets are marketed by Strides Pharma Inc.Furthermore, in November 2012, Sagent Pharmaceuticals introduced acetazolamidefor injection, specified for adjunctive treatment of edema due to congestiveheart failure, drug-induced edema, centrencephalic epilepsies, and chronicsimple glaucoma, secondary glaucoma, and preoperatively in acute angle-closureglaucoma.
Key takeaways of theAcetazolamide Market:
The global acetazolamide marketis expected to expand at a CAGR of 4.8% during the forecast period (2018 –2026), owing to high prevalence of glaucoma, edema, and its associated riskfactors such as diabetes, family history of glaucoma, high blood pressure,among others.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/acetazolamide-market-2396
Among formulation, tabletssegment accounted for major market share in 2017. Acetazolamide is majorly usedin the treatment of glaucoma and altitude sickness, owing to increasing dosingpreference and clinical effectiveness of acetazolamide. For instance, accordingto data published in the BMJ journal in September 2012, daily doses of 250 mg,500 mg, and 750 mg acetazolamide was found to be effective in preventing acutemountain sickness.
Among applications, glaucomasegment held major market share, in 2017. Acetazolamide is approved andincreasingly used as carbonic anhydrase inhibitor in the treatment of glaucoma,by offering substantial pressure relief effect.
Among distribution channel,hospitals pharmacies segment held major market share in 2017. Hospitalpharmacies act as key channel in distribution of acetazolamide medication toglaucoma patients who are treated in hospital.
Some of the major playersoperating in global acetazolamide market include Teva Pharmaceutical IndustriesLtd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), HeritagePharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd.,Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc.,Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2396
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
